Eli Lilly and Co
What investors need to know about weight loss medicines and suicide risk
Investors would be forgiven if talk of a potential suicide risk associated with a new class of diabetes and weight loss drugs led to skittishness last week. Prior attempts to treat overweight or obese patients with medications were often plagued with side effects and drug recalls. Those earlier medications often didn’t seem like the results […]
Read More
Shares generating the most important moves midday: UnitedHealth, JPMorgan Chase, Microsoft, JetBlue and far more
A UnitedHealth Group health insurance plan card is observed in a wallet, Oct.14, 2019. Lucy Nicholson | Reuters Check out out the corporations creating headlines in midday trading. JPMorgan Chase — Shares fell somewhat even immediately after the bank documented more robust-than-predicted outcomes for the next quarter, as it benefited from increased interest costs and […]
Read More
Eli Lilly to acquire obesity drug maker Versanis for $1.9 billion
Eli Lilly and Company, Pharmaceutical company headquarters in Alcobendas, Madrid, Spain. Cristina Arias | Cover | Getty Images Eli Lilly on Friday said it will acquire Versanis, a privately held obesity drug maker, for up to $1.93 billion to boost the pharmaceutical giant’s weight loss treatment portfolio. Eli Lilly agreed to pay Versanis shareholders in […]
Read More
Uninsured Americans pay high costs for an insulin Eli Lilly vowed to price at $25, Sen. Warren says
An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021. Mike Segar | Reuters Uninsured Americans pay nearly $98 on average for a vial of Eli Lilly‘s generic insulin, even after the company pledged to cut the product’s list price to $25 per vial, […]
Read More
EU expands Wegovy, Ozempic probe over suicide risks to include other weight loss, diabetes drugs
In this photo illustration, boxes of the diabetes drug Ozempic rest on a pharmacy counter on April 17, 2023 in Los Angeles, California. Mario Tama | Getty Images The European Union’s drug regulator on Tuesday said it has broadened an investigation into the risk of suicidal thoughts and self-injury among patients taking Novo Nordisk‘s Ozempic, […]
Read More
Few patients continue weight loss drugs like Wegovy after a year — but health costs soar for all
A selection of injector pens for the Wegovy weight loss drug are shown in this photo illustration in Chicago, Illinois, March 31, 2023. Jim Vondruska | Reuters Only around one-third of patients prescribed weight loss drugs such as Novo Nordisk‘s blockbuster injection Wegovy continued to take it a year later — but total health-care costs […]
Read More
People should stop taking Ozempic, Wegovy obesity drugs before surgery, doctors group says
In this photo illustration, a box of the diabetes drug Ozempic rests on a pharmacy counter on April 17, 2023 in Los Angeles, California. Mario Tama | Getty Images People on diabetes and weight loss drugs such as Novo Nordisk‘s Ozempic and Wegovy should stop taking them before having elective surgery to reduce the risk […]
Read More
Ageing populations are producing important chances, fund supervisor suggests. Here is in which he’s investing
Populations across the globe are residing for extended, and that is opening up a slew of financial commitment chances, in accordance to fund manager Dani Saurymper. “This is an investable area now, and it will develop into increasingly much more pertinent and obvious as we go as a result of ahead into the long run,” […]
Read More
As drugmakers race to develop the next big weight loss pill, Eli Lilly may have an edge
An Eli Lilly & Co. logo is seen on a box of insulin medication in this arranged photograph at a pharmacy in Princeton, Illinois. Daniel Acker | Bloomberg | Getty Images Drugmakers are jockeying to capitalize on the next major innovation coming to the blockbuster weight loss industry: effective, convenient and potentially affordable obesity pills. […]
Read More
Eli Lilly’s weight loss drugs trounce sky-high expectations, boosting the stock
Eli Lilly bested investors’ super-high expectations at the American Diabetes Association conference this week, cementing its leadership in metabolic medicine and prompting Wall Street analysts to take another look at their sales forecasts. Across the board, analysts said the news is likely to lend support Lillto y shares, which have already popped more than 26% […]
Read More